Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks


Expansion of Non-Invasive Prenatal Testing

Noninvasive prenatal testing (NIPT) or screening (NIPS) has been widely adopted and its use no longer questioned in high risk settings. However, over the past year, further research and payor models have demonstrated the utility of extending NIPT to the average risk population potentially impacting approximately 5,000,000 pregnancies per year. This session will review the data on NIPT performance in the average risk population, as well as provide clinical and reimbursement perspective.


Kimberly A. Martin, M.D.,  FRCSC, FCCMG, FACOG, FACMG, Medical Director for Reproductive Testing, Natera

Dr. Martin received her medical degree from McGill University, Montreal,Canada.  She completed her residency in Obstetrics and Gynecology at the University of Western Ontario, London, Canada and a fellowship in Clinical Genetics at the University of British Columbia, Vancouver, Canada. Read Full Bio

Peter Benn, D.SC., Professor, Genetics and Genome Sciences, University of Connecticut

Recognizing that prenatal screening and diagnosis is being radically changed by the discovery of cell-free DNA in maternal plasma, Dr Benn has been focused on the technical, practical, economic and ethical issues associated with the introduction of this technology. Read Full Bio

Anthony Gregg, M.D., Professor and Chief Material-Fetal Medicine, Director of Obstetrics at the University of Florida

Tony Gregg, M.D., is Professor, and Chief, of Maternal-Fetal Medicine, Director of Obstetrics at the University of Florida. He received training at Loyola University, the University of Iowa, and Baylor College of Medicine. Read Full Bio

Web Analytics